Metavalis
Branson
About Metavalis
Metavalis Inc. is a Strategic Bioengineering Firm waging a disciplined war on intractable genetic diseases. Founded by a U.S. Army veteran of the 82nd Airborne Division, the company operates on a codified "Warrior Ethos," translating military principles of high velocity execution and resilience into the field of biotechnology. Unlike traditional biotech startups that rely on fragmented systems, Metavalis is an enterprise powered by The Metavalis OS a proprietary, digital command infrastructure. This ecosystem integrates R&D, finance, and strategic intelligence into a single "pane of glass," allowing for capital efficiency and execution speed that defies industry standards. Core Technology: The Engine Metavalis is the architect of a synergistic, two part platform designed to solve the fundamental failures of current genetic medicines. The Smart LNP 3.0 Platform: A next generation delivery system designed from first principles. It utilizes a novel rapidly biodegradable ionizable lipid for chronic safety and a proprietary stealth polymer (replacing PEG) to eliminate immunogenicity, enabling safe, lifelong re-dosing. (Disclaimer this new technology is patent pending only and preparing to enter pre clinical trials. No human clinical trials have been preformed and all statements haven't been evaluated or approved by the FDA. These statements are based on prophetic claims based on our provisonal patent application with The United States Patent Office. The saRNA Engine: Self Amplifying RNA payloads designed to replicate within the cell, creating a "molecular factory" that drives profound, durable protein expression from a minimal dose. Operational Superiority: The Metavalis OS To de risk execution, the company has built a Fortune 500 grade digital infrastructure typically unseen at the pre-seed stage. Sentinel SOC: A military grade Security Operations Center providing real time threat monitoring, biometric identity assurance, and "Air Gapped" data protection. The Oracle: A RAG powered AI intelligence engine that instantly retrieves and synthesizes proprietary scientific and corporate data for decision support. The Codex: A digitized repository of strategic doctrine, ensuring every operational decision aligns with the company's "Failure Doctrine" and "Freedom to Operate" mandates. Lead Program: The company's lead campaign, The Lumina Program, is developing a first in-class therapeutic for Crigler-Najjar Syndrome Type 1 (CNS1), aiming to provide a "long term therapeutic curative" alternative to liver transplantation. We are, Forged In Fire. Built To Win!
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $40.0K
- Funding stage: Seed
- Last round: Angel (Apr 2026)
- Website: metavalis.com
- Phone: (417) 243-9965
Industries & Categories
Biotechnology, Genetics, GovTech, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/metavalis-15606 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.